Phase II study of pemetrexed plus oxaliplatin for platinumresistant advanced or metastatic non-small cell lung cancer patients

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 640-643

  Lee, Dae Ho ^a   Choi, Chang Min ^a   Kim, Sang We ^a   Suh, Cheolwon ^a   Lee, Jung Shin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Non small cell lung cancer; Oxaliplatin; Pemetrexed; Second line

Indexed keywords

OXALIPLATIN; PEMETREXED; PLATINUM; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; NEUROPATHY; PRIORITY JOURNAL; SURVIVAL TIME; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FOLLOW UP; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84866273337     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9944-6     Document Type: Article

References (17)

1. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087-100.
2. Barlesi F, Jacot W, Astoul P, et al. Second-line treatment for advanced non-small cell lung cancer: a systemic review. Lung Cancer. 2006;51:159-72.
3. Azzoli CG, Giaccone G, Temin S. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2010;6: 39-43.
4. Rusthoven J, Eisenhauer E, Butts C, et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced nonsmall- cell lung cancer: a phase II study. J Clin Oncol. 1999;17:1194-9.
5. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small cell lung cancer. Ann Oncol. 2002;13:737-41.
6. Manegold C, Von Pawel J, Pirker R, et al. Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: a multicenter phase II trial. Ann Oncol. 2000;11:435-40.
7. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer. 2001;92:595-600.
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97.
9. Raymond E, Chaney S, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053-71.
10. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel. Biochem Pharmacol. 1996;2:1855-65.
11. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European organization for research and treatment of cancer gynecology group. J Clin Oncol. 2000;18:1193-202.
12. Soulie P, Garrino C, Bensmaine MA, et al. Antitumor activity of oxaliplatin/cisplatin based combination therapy in cisplatinrefractory germ cell cancer patients. J Cancer Res Clin Oncol. 1999;125:707-11.
13. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol. 2004;15:1123-9.
14. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
15. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-63.
16. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010;28:614-9.
17. Heist RS, Fidias P, Huberman M, et al. Aphase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(10):1153-8.